echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Four development trends of China's biomedical industry in 2020

    Four development trends of China's biomedical industry in 2020

    • Last Update: 2020-01-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] at present, many countries regard the biomedical industry as a strategic industry of priority development in the 21st century, and China is no exception As one of the strategic emerging industries in China, the sales revenue of biomedical industry is increasing from 2009 to 2019 According to the industry forecast, the global biomedical industry will enter a period of rapid development in 2020 So, what is the specific development trend? In 2020, there are four major trends in the development of China's biomedical industry The competition among biomedical enterprises is intensified Biomedical industry has always been a typical "high input, high risk, high output and long cycle" industry However, with the continuous improvement of people's living standards, the continuous improvement of their health concerns, and the maturity of new biomedical technologies, the scale of China's biological market has maintained a rapid growth Therefore, the biomedical industry is also regarded as a sunrise industry, and it is expected that the industry scale will be larger and larger in the future At present, many domestic biomedical enterprises have opened the layout in advance In this context, with the rapid development of global biomedical industry in 2020, the concentration of biomedical industry will continue to improve, and the competition between enterprises will become increasingly fierce in the future At that time, the enterprises that have mastered the core technology and can continuously improve the ability of independent innovation will undoubtedly be more competitive in the development Gradually participate in global competition In recent years, in the field of biomedical innovation, our government has issued strong policies for many times, not only focusing on improving the innovation ability and industrialization level of biomedical, but also encouraging the development of innovative industries from multiple dimensions, accelerating the process of registration and listing, realizing the localization of related fields, and cultivating a number of products with core independent competitiveness Therefore, in the environment, the pattern of Chinese medicine has changed greatly, and a batch of domestic innovative drugs have emerged For example, on December 20, Xuanning, a hypertension drug of Shiyao group, was reviewed and approved by the food and Drug Administration of the United States, becoming the first innovative drug fully approved by the United States by Chinese enterprises At present, from the overall point of view, Chinese pharmaceutical companies, whether it is traditional Chinese medicine, generic drugs or innovative drugs, are gradually succeeding in exploring and familiar with the regulations and standards of overseas markets In the future, with the increasing integration of China and the world, the mode of domestic pharmaceutical enterprises participating in global competition will become more and more diversified, such as granting overseas development rights and interests license of the project to overseas companies to jointly explore the international market, and making equity investment in foreign innovative pharmaceutical enterprises Actively explore new technologies In fact, there are still some problems in the development of biotechnology in China, such as less independent and original achievements, key core technologies still being controlled by people, low efficiency of technology transformation, and insufficient capacity for industrial development It is urgent to strengthen the innovation capacity of biotechnology   It is understood that in recent years, with the breakthrough of artificial intelligence technology, data and intelligent technology have become more and more important in the development of biomedical industry Nowadays, a large number of pharmaceutical enterprises in the world, such as Merck, novatis, Roche, etc., have begun to explore the combination of artificial intelligence and new drug research and development, accelerate the new drug research and development process through intelligent technology, improve research and development efficiency, and main intelligent application packages Including the development of new drug design, physical and chemical property prediction, pharmaceutical analysis, disease diagnosis target, drug combination and other research Affected by the environment, China is also accelerating the integration of biomedicine and artificial intelligence industry, and enhancing the competitiveness of biomedical industry According to the analysis report on the market prospect and investment strategic planning of China's artificial intelligence industry in 2018-2023, the scale of China's artificial intelligence + medical market continues to grow, exceeding 13 billion yuan in 2017, with a year-on-year growth of 40.7% In the next five years, the intelligent medical enterprises may face a huge market of more than 20 billion yuan, which will attract more capital and enterprises to chase Cro, CMO and CSO will develop rapidly With the deepening of domestic medical reform, the consistency evaluation of generic drugs, and the introduction of heavy policies such as purchasing with volume, the biomedical industry has higher and higher requirements for innovation and stricter control over the circulation link How to quickly improve the innovation ability, and based on the scale effect to enhance the research and development, production and circulation service ability to reduce the marginal cost, will be a new challenge for the industry In this case, in the next few years, the domestic biomedical industry will gradually appear in the cro, CMO, CSO fields, and at present, the leading enterprises of the domestic biomedical industry, which are relatively advanced in development, will run fast through capital Take the cro field as an example According to the data of Frost & Sullivan consulting, the market size of China's cro industry has risen to $5.9 billion in 2018 The industry expects that by 2023, the domestic cro market will reach US $21.4 billion, with an average annual growth rate of 29.8% in 2019-2023.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.